Assessment of complex treatment influence on systemic inflammation in overweight type 2 diabetes patients.

Said OV, Velychko VI, Danylchuk HO

Wiadomosci lekarskie (Warsaw, Poland : 1960)1 Jan 2018Cited by 2 (Europe PMC)

PMID30267490PepBankPUB-30267490

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, BMI fell significantly with liraglutide monotherapy (from 28,59 to 25,87 kg/m2).
In plain wordsIn overweight adults with type 2 diabetes, body mass index fell with liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseBMI change with liraglutide monotherapy
Study
n = 30
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 1.8 mg/dayAs given in this study (human).
Source sentences
Summary
whereas such decrease in the liraglutide monotherapy group was from 28,59±2,5 kg/m2 to 25,87±2,3 kg/m2
2 context sentences(design, population, supporting numbers)
Summary · context
Patients in the second group received liraglutide up to 1.8 mg/day (n=30).
Summary · context
Meterials and methods: The study included 80 overweight patients with type 2 diabetes.
Report a problemFND-3026749001

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, a combination of metformin and liraglutide lowered BMI from 28,48 to 23,9 kg/m2.
In plain wordsIn overweight adults with type 2 diabetes, metformin plus liraglutide together lowered body mass index.
Peptide
Liraglutide
Outcome
DecreaseBMI change with metformin plus liraglutide
Study
n = 30
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Main group achieved a decrease in BMI from 28,48±2,1 kg/m2 to 23,9±1,8 kg/m2
2 context sentences(design, population, supporting numbers)
Summary · context
Patients in the third (main) group received a combination of metformin (up to 2500 mg/day) and liraglutide up to 1.8 mg/day (n=30).
Summary · context
Meterials and methods: The study included 80 overweight patients with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3026749002
03HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, metformin plus liraglutide lowered TNF-α from 10,14 to 7,49 pg/ml.
In plain wordsIn overweight adults with type 2 diabetes, metformin plus liraglutide together lowered an inflammation marker, TNF-α.
Peptide
Liraglutide
Outcome
DecreaseTNF-alpha level with metformin plus liraglutide
Study
n = 30
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Main group saw a decrease in TNF-α levels from 10,14±0,6 to 7,49±0,33 pg/ml (<0,001)
2 context sentences(design, population, supporting numbers)
Summary · context
Patients in the third (main) group received a combination of metformin (up to 2500 mg/day) and liraglutide up to 1.8 mg/day (n=30).
Summary · context
Meterials and methods: The study included 80 overweight patients with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3026749003
04HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, metformin plus liraglutide lowered IL-6 from 11,12 to 7,84 pg/ml.
In plain wordsIn overweight adults with type 2 diabetes, metformin plus liraglutide together lowered an inflammation marker, IL-6.
Peptide
Liraglutide
Outcome
DecreaseIL-6 level with metformin plus liraglutide
Study
n = 30
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
IL-6 levels from 11,12±0,7 to 7,84±0,62 pg/ml (<0,001)
2 context sentences(design, population, supporting numbers)
Summary · context
Patients in the third (main) group received a combination of metformin (up to 2500 mg/day) and liraglutide up to 1.8 mg/day (n=30).
Summary · context
Meterials and methods: The study included 80 overweight patients with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3026749004
05HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, liraglutide-based therapy was more efficient than metformin in lowering inflammatory cytokines, with TNF-α and IL-6 most sensitive.
In plain wordsIn overweight adults with type 2 diabetes, liraglutide-based treatment lowered inflammation markers more than metformin did.
Peptide
Liraglutide
Outcome
DecreaseProinflammatory cytokines with liraglutide-based therapy
Study
n: not reported in source
Comparator
Metformin
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Liraglutide was more efficient in lowering inflammatory cytokine concentrations with TNF-α and IL-6 being more sensitive to its effects.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim: Our goal was to assess influence of liraglutide in complex therapy on proinflammatory cytokine levels in overweight patients with type 2 diabetes and compare it with metformin.
Summary · context
Meterials and methods: The study included 80 overweight patients with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3026749005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.